By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Tech

Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR

PRNW Agency
Last updated: 04/02/2025 11:54 PM
PRNW Agency
Share
5 Min Read
Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR
SHARE
Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR

GenAI-powered solution delivers clinical study reports in minutes with 30%–50% faster turnarounds, 90% ICH-E3-aligned accuracy, and substantial cost savings.

BERKELEY HEIGHTS, N.J., Feb. 4, 2025 /PRNewswire/ — Axtria Inc., a global cloud software and data analytics company for the life sciences industry, announces groundbreaking advancements in its Clinical Solutions practice with the launch of Axtria Rapid CSR, an innovative use of Generative AI for the processing and automation of clinical study report (CSR) development. Axtria Rapid CSR has been trained and tested to reduce the generation of these reports by 30%–50% for most large-scale phase III clinical trials.

“We developed Axtria Rapid CSR to enhance efficiency in manual, error-prone tasks like interpreting clinical study data, deciphering complex tables and graphs, and analyzing annotated case report forms to rapidly develop an initial, complete CSR,” said Luke Dunlap, Principal and Head of Clinical Solutions at Axtria. “We have seen significant advances in our ability to generate accurate medical writing, particularly in the areas of safety and efficacy where our solution draws critical inferences from multiple study data inputs, even for the most complex sections of a CSR.”

Axtria Rapid CSR is capable of supporting studies of all sizes, from early-phase trials to post-surveillance. Watch a short video here.

- Advertisement -
    • What this Does: Axtria Rapid CSR transforms clinical study reporting by streamlining the entire CSR authoring workflow, combining the power of artificial intelligence with human expertise to deliver superior results. This leverages multiple LLM approaches to consume data from thousands of file formats, summarizing both structured and unstructured source documents. Results adhere to ICH-E3 guidelines for formatting requirements and can cross-reference multiple tables to support a single summary across sections.
    • Impact it Delivers: Axtria Rapid CSR delivers data extraction and interpretation with over 90% accuracy in completed experiments and generates report sections in minutes, enabling quicker regulatory submissions.

About Axtria’s Clinical Solutions
Axtria’s Clinical Solutions practice area drives value realization for life sciences companies through groundbreaking clinical innovations and measurable results. Our expertise lies in solving complex challenges in life sciences research and development through cutting-edge data science, generative AI, and advanced information management solutions. We specialize in modernizing clinical data workflows, enhancing clinical program management, and running late-phase investigations, leveraging proprietary technology accelerators to deliver measurable improvements in efficiency and quality. Our team is dedicated to supporting clinical research and trials with tailored solutions, robust analytics, and seamless execution to address the most pressing needs in the industry.

About Axtria’s Products and Solutions
Axtria is proud to work with 16 of the top 20 life sciences companies, globally. From our roots as a trusted consultant to our status as one of the world’s leading providers of cloud-based pharmaceutical management software, Axtria powers digital transformations in life sciences. Our experts call upon years of domain experience in the industry to guide pharma giants from brand launches to retirement. Our products go even further. Axtria InsightsMAx™ helps everyone from the C-suite to junior associates uncover trends to make better decisions. Axtria SalesIQ™ helps optimize field forces and provider engagements. Axtria CustomerIQ™ leverages AI-enabled next-best-action omnichannel choices. Axtria MarketingIQ™ turns investment analyses into pinpoint strategies. And Axtria DataMAx™ and DataMAx™ for Emerging Pharma is the data management framework that pulls it all together with best-in-class security and integration. 

About Axtria
Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. The company is a leading global provider of award-winning cloud software and data analytics to the life sciences industry. We’re proud to deliver proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action, enabling them to earn superior returns on their investments. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and taking actions that advance societal goals. For more information, please visit www.axtria.com.

Logo – https://mma.prnewswire.com/media/2256316/Axtria_transparent_bg_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/axtria-harnesses-genai-to-slash-timelines-and-boost-accuracy-in-clinical-study-reporting-with-axtria-rapid-csr-302366734.html

- Advertisement -

You Might Also Like

Equiti Group Appoints Yiannos Xenophontos as Group Head of Trading to Support Global Growth

Monish Gujral Revolutionizes Restaurant Franchising with Innovative FOCM Model

Towards the Light: Co-creating a New Global Journey in the AI Field The Grand 2025 AI Intelligent Development Summit

EQUITIES.COM WELCOMES NIDHI CHADDA FROM ENZO ADVISORS AS PARTNER AND GUEST CONTRIBUTOR

EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation

TAGGED:accuracyanalyticsaxtriaberkeleyboostclinicalcloudcompanycomplexcostcsrdatadeliversfasterfebgenaigenaipoweredglobalharnessesheightsichealignedincminutesrapidreportreportingreportssavingsslashsoftwaresolutionsolutionsstudysubstantialtimelinesturnaroundsuncategorized

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article SquaredFinancial Launches its Exclusive Bonus Promotion to Offer Better Trading Opportunities SquaredFinancial Launches its Exclusive Bonus Promotion to Offer Better Trading Opportunities
Next Article Colossyan Leads AI Innovation with Strong 2024 Performance Colossyan Leads AI Innovation with Strong 2024 Performance

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
Health 26/06/2025
MEME COINS INC., a Controlled Subsidiary of DOGP, to Acquire 2 Billion DOG Tokens from Tipestry
MEME COINS INC., a Controlled Subsidiary of DOGP, to Acquire 2 Billion DOG Tokens from Tipestry
Health 26/06/2025
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Health 26/06/2025
Gold H2 Delivers First Successful Subsurface Bio-Stimulated Hydrogen Production Field Trial
Gold H2 Delivers First Successful Subsurface Bio-Stimulated Hydrogen Production Field Trial
Health 26/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?